What the FDA labels say about taking them together
Cyclosporine and potassium phosphate dibasic/potassium phosphate monobasic
Potassium phosphate dibasic/potassium phosphate monobasic's FDA label of December 31, 2024 names cyclosporine in its drug interactions section; cyclosporine's label does not name potassium phosphate dibasic/potassium phosphate monobasic itself but warns about its class (potassium salts). The potassium phosphate dibasic/potassium phosphate monobasic label: “Products that Increase Serum Potassium Administration of potassium phosphates injection to patients treated concurrently or recently with products that increase serum potassium increases the risk of severe and …”
Check it at the source: the cyclosporine FDA label on DailyMed (effective August 10, 2026, Novartis Pharmaceuticals Corporation); the potassium phosphate dibasic/potassium phosphate monobasic FDA label on DailyMed (effective December 31, 2024, Amneal Pharmaceuticals Private Limited).
What does the cyclosporine label say about potassium phosphate dibasic/potassium phosphate monobasic?
Cyclosporine's label does not name potassium phosphate dibasic/potassium phosphate monobasic itself; it warns about its class (potassium salts):
Cyclosporine label, drug interactionsCaution is also required when cyclosporine is coadministered with potassium sparing drugs (e.g., angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists), potassium-containing drugs as well as in patients on a potassium rich diet.
Source: FDA drug label (Neoral), Novartis Pharmaceuticals Corporation, effective August 10, 2026 (SPL set 94461af3-11f1-4670-95d4-2965b9538ae3), via openFDA; the full label on DailyMed
What does the potassium phosphate dibasic/potassium phosphate monobasic label say about cyclosporine?
Potassium phosphate dibasic/potassium phosphate monobasic label, drug interactionsProducts that Increase Serum Potassium Administration of potassium phosphates injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3) ].
Source: FDA drug label (Potassium Phosphates, NDA218343), Amneal Pharmaceuticals LLC, effective September 1, 2025 (SPL set dce22c93-aa48-48a9-ac8b-716400d33c9e), via openFDA
Source: FDA drug label (POTASSIUM PHOSPHATES), Amneal Pharmaceuticals Private Limited, effective December 31, 2024 (SPL set 89136c51-a60b-4269-bd05-9489f060a734), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cyclosporine | Potassium phosphate dibasic/potassium phosphate monobasic | |
|---|---|---|
| Labeled for | Organ transplant rejection, Rheumatoid arthritis | n/a |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $1.04 per unit 0.05% eye emulsion | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once